Last reviewed · How we verify

Oral typhoid fever vaccine

Helsinki University Central Hospital · FDA-approved active Biologic Quality 5/100

Oral typhoid fever vaccine is a Biologic drug developed by Helsinki University Central Hospital. It is currently FDA-approved. Also known as: Vivotif®.

At a glance

Generic nameOral typhoid fever vaccine
Also known asVivotif®
SponsorHelsinki University Central Hospital
ModalityBiologic
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Oral typhoid fever vaccine

What is Oral typhoid fever vaccine?

Oral typhoid fever vaccine is a Biologic drug developed by Helsinki University Central Hospital.

Who makes Oral typhoid fever vaccine?

Oral typhoid fever vaccine is developed and marketed by Helsinki University Central Hospital (see full Helsinki University Central Hospital pipeline at /company/helsinki-university-central-hospital).

Is Oral typhoid fever vaccine also known as anything else?

Oral typhoid fever vaccine is also known as Vivotif®.

What development phase is Oral typhoid fever vaccine in?

Oral typhoid fever vaccine is FDA-approved (marketed).

Related